Novartis (NOVN.SW) stock price, revenue, and financials

Novartis market cap is CHF182.8 b, and annual revenue was $48.66 b in FY 2020

CHF182.8 B

NOVN.SW Mkt cap, 26-Apr-2021

$48.7 B

Novartis Revenue FY, 2020
Novartis Revenue growth (FY, 2019 - FY, 2020), %3%
Novartis Gross profit (FY, 2020)33.5 B
Novartis Gross profit margin (FY, 2020), %68.9%
Novartis Net income (FY, 2020)8.1 B
Novartis EBIT (FY, 2020)10.2 B
Novartis Cash, 31-Dec-20209.7 B
Novartis EV211.2 B

Novartis Revenue

Novartis revenue was $48.66 b in FY, 2020 which is a 2.6% year over year increase from the previous period.

Embed Graph

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 19.8% from Sandoz and 80.2% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 5.3% from China, 5.8% from Japan , 33.9% from United States, 5.0% from France, 9.3% from Germany and 40.8% from Other

Novartis Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

51.9b47.4b48.7b

Revenue growth, %

6%(9%)3%

Cost of goods sold

17.1b13.2b15.1b

Gross profit

34.8b34.2b33.5b

Gross profit Margin, %

67%72%69%

R&D expense

9.1b9.4b9.0b

General and administrative expense

16.5b14.4b14.2b

Operating expense total

26.6b25.2b26.4b

EBIT

8.2b9.1b10.2b

EBIT margin, %

16%19%21%

Interest expense

957.0m850.0m869.0m

Pre tax profit

13.8b8.9b9.9b

Income tax expense

1.2b1.8b1.8b

Net Income

12.6b11.7b8.1b

EPS

5.45.1352.0

Novartis Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

13.3b11.1b9.7b

Accounts Receivable

8.7b8.3b8.2b

Inventories

7.0b6.0b7.1b

Current Assets

35.6b29.5b29.7b

PP&E

15.7b12.1b12.3b

Goodwill

35.3b26.5b30.0b

Total Assets

145.6b118.4b132.1b

Accounts Payable

5.6b5.4b5.4b

Short-term debt

9.7b7.3b10.1b

Current Liabilities

29.6b28.3b33.1b

Long-term debt

22.5b22.1b28.0b

Non-Current Liabilities

37.3b34.6b42.3b

Total Debt

32.1b29.3b38.0b

Total Liabilities

66.9b62.8b75.4b

Common Stock

944.0m936.0m913.0m

Total Equity

78.7b55.6b56.7b

Debt to Equity Ratio

0.4 x0.5 x0.7 x

Debt to Assets Ratio

0.2 x0.2 x0.3 x

Financial Leverage

1.8 x2.1 x2.3 x

Novartis Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

12.6b7.1b8.1b

Depreciation and Amortization

6.9b5.8b6.1b

Accounts Receivable

(569.0m)(980.0m)137.0m

Inventories

(533.0m)(382.0m)(543.0m)

Accounts Payable

309.0m553.0m(324.0m)

Cash From Operating Activities

14.3b13.6b13.7b

Purchases of PP&E

(1.8b)(1.4b)(1.3b)

Cash From Investing Activities

(5.6b)(2.2b)(13.2b)

Short-term Borrowings

1.7b(1.6b)2.3b

Long-term Borrowings

(366.0m)(3.5b)(2.3b)

Dividends Paid

(7.0b)(6.6b)(7.0b)

Cash From Financing Activities

(4.2b)(13.6b)(2.2b)

Net Change in Cash

4.4b(2.2b)(1.5b)

Interest Paid

826.0m793.0m703.0m

Novartis Ratios

USDQ1, 2018

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.9 x

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019Q4, 2020

Clinical Data Readouts

30

Major Approvals (US, EU, JP)

20161615

Major Submissions (US, EU, JP)

1424162030

Patients Reached

972 m965 m927 m

Phase I/II Trials Products

114118

Phase I/II Trials Products (Oncology)

5751

Phase I/II Trials Products (Pharmaceuticals)

5767

Phase III Trials Products

3729373844

Phase III Trials Products (Biosimilars)

11

Phase III Trials Products (Oncology)

2022

Phase III Trials Products (Pharmaceuticals)

1721

Projects Entering Development Pipeline

859

Registration Phase Products

135

Registration Phase Products (Oncology)

3

Registration Phase Products (Pharmaceuticals)

105

US FDA Breakthrough Therapy Designations

56

Novartis Sustainability Metrics

 FY, 2019

Water Used (Cooling)

55.5 m cubic meters

Water Used (Contact)

11.2 m cubic meters

Water Used

66.7 m cubic meters

Water Recycled

14.7 m cubic meters

Water Purchased (Suppliers)

9.3 m cubic meters

Water Lost

1.2 m cubic meters

Water Emissions (Total Suspended Solids)

198.2 tonnes

Water Emissions (Phosphate)

34.7 tonnes

Water Emissions (Nitrogen)

207.5 tonnes

Water Emissions (Chemical Oxygen Demand)

1.84 k tonnes

Water Discharged

9.9 m cubic meters

Total Recordable Incident Rate

0.36

Purchased Energy Used (Total)

6.68 m GJ

On-Site Generated Energy Used (Total)

6.19 m GJ

Nonhazardous Waste Recycled, percent

81.7%

Nonhazardous Waste (Recycled)

57.7 k tonnes

Nonhazardous Waste (Landfilled)

4.1 k tonnes

Nonhazardous Waste (Incinerated)

8.4 k tonnes

Nonhazardous Waste (Bio/Chemical Treatment)

400 tonnes

Lost Time Illness Rate

0.18

Hazardous Waste Recycled, percent

58.8%

Hazardous Waste (Recycled)

58.8 k tonnes

Hazardous Waste (Incinerated)

37.2 k tonnes

Hazardous Waste (Bio/Chemical Treatment)

4 k tonnes

Greenhouse Gas Emissions (Scope 3, Business Travel)

191.3 k tonnes

Greenhouse Gas Emissions (Scope 2, Market-Based)

411.6 k tonnes

Greenhouse Gas Emissions (Scope 2, Location-Based)

564.5 k tonnes

Greenhouse Gas Emissions (Scope 1, Fuel Combustion)

356.2 k tonnes

Greenhouse Gas Emissions (Scope 1, Fleet Vehicles)

128.4 k tonnes

Greenhouse Gas Emissions (Scope 1 and Scope 2) Intensity

18.9 metric tons of carbon dioxide equivalent per mio USD

Greenhouse Gas Emissions (Scope 1 and Scope 2)

896.1 k tonnes

Environmental Fines or Penalties Paid

$11.3 k

Energy Used from Renewable Energy Sources

2.25 m GJ

Energy Used

12.75 m GJ

Energy Use Intensity per employee

137.2 GJ/employee

Energy Use Intensity

314.8 GJ/100 square meters

Energy Sold

130 k GJ

Air Emissions (Sulfur Oxide)

4.56 tonnes

Air Emissions (Particulate Matter)

12.91 tonnes

Air Emissions (Non-Halogenated Volatile Organic Compounds)

406.82 tonnes

Air Emissions (Nitrogen Oxides)

236.32 tonnes

Air Emissions (Halogenated Volatile Organic Compounds)

26.59 tonnes

Novartis Human Capital

Job Roles

FY, 2019FY, 2018FY, 2017
Male (Board), percent18.8%18.8%19.3%
Female (Leadership), percent7.8%7%6.8%
Male (Middle Management), percent13.8%14.3%14.5%
Female (Middle Management), percent11.3%10.8%10.5%
Male (Leadership), percent17.3%18%18.3%
Female (Senior Management), percent9.5%9%8.5%
Male (Senior Management), percent15.5%16%16.5%
Female (Board), percent6.3%6.3%5.8%
FY, 2019FY, 2018FY, 2017
Female, percent44%42%41%
Male, percent56%58%59%

Novartis Employee Rating

4.25238 votes
Culture & Values
4
Work/Life Balance
3.9
Senior Management
3.5
Salary & Benefits
4
Career Opportunities
3.7
Source